Helen Bygott

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

L. Ranganath, Anna M. Milan, Andrew T. Hughes et al. · Annals of the Rheumatic Diseases · 2014 · 157 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial

L. Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux et al. · The Lancet Diabetes & Endocrinology · 2020 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria

L. Ranganath, Anna M. Milan, Andrew T. Hughes et al. · Journal of Inherited Metabolic Disease · 2019 · 29 citations · Full text

Pharmacy, Nephrology, Physiology +13

Vitiligo, alkaptonuria, and nitisinone—A report of three families and review of the literature

L. Ranganath, Milad Khedr, Leanne A. Evans et al. · JIMD Reports · 2021 · 12 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +8